|Bid||3.0400 x 4000|
|Ask||3.0500 x 800|
|Day's Range||3.0300 - 3.3000|
|52 Week Range||1.2900 - 4.0600|
|Beta (3Y Monthly)||1.91|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 9, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.50|
Achillion Pharmaceuticals, Inc.'s (NASDAQ:ACHN) most recent earnings announcement in December 2018 suggested company earnings became less negative compared to the previous year's level - great news for investors Today IRead More...
Achillion (ACHN) encourages with narrower-than-expected loss in Q4. However, the company did not generate any revenues in the period.
BLUE BELL, Pa., March 08, 2019 -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and.
- Phase 2 trial enrollment on schedule in PNH combo, interim data expected in Q2:2019 -- Phase 2 trial enrollment on schedule in C3G, 24 sites recruiting -- Next-generation.
A Connecticut biopharmaceutical company, with growth in its plans, has moved its executive offices and clinical operations to suburban Philadelphia. Achillion Pharmaceuticals of New Haven, Conn., has opened a 12,000-square-foot office in Blue Bell where the company has 30 employees and expects to add more. Joe Truitt, Achillion's president and CEO, said the move to Blue Bell was done with future hiring in mind.
NEW HAVEN, Conn., Feb. 21, 2019 -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients.
NEW HAVEN, Conn., Feb. 19, 2019 -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients.
NEW YORK, Feb. 12, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Achillion Pharmaceuticals, Inc. (ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced the appointment of Brian Di Donato to the position of Senior Vice President and Chief Financial Officer, effective immediately. Mr. Di Donato has over 20 years of financial and leadership experience and will assume responsibility for finance, accounting and treasury as well as continue to lead investor relations. “Brian joined the Achillion team in August 2018 and has already made significant contributions alongside the new management team as we accelerate our clinical programs and prepare for registrational trials,” commented Joseph Truitt, President and Chief Executive Officer of Achillion.
- ACH-5228, with improved potency and half-life, increases alternative pathway inhibition -- Achillion planning Investigational New Drug (IND) submission in fourth quarter of.
Alexion's (ALXN) Ultomiris meets primary endpoint in a phase III study conducted on complement inhibitor-naive patients with aHUS.
A volatile stock market dished out an extra dose of punishment to riskier assets, including these three small-cap pharma companies.
The biotechnology sector really got hammered in 2018. In December the markets took many quality small cap biotechs down to historic low prices, observes Bill Mathews, small cap expert and editor of The Cheap Investor.
Bristol-Myers Squibb Co (NYSE: BMY) announced a deal to buy Celgene Corporation (NASDAQ: CELG) in a cash and stock transaction with an equity value of approximately $74 billion. Separately, the company announced FDA approval for an expanded indication for its Sprycel tablets to include the treatment of pediatric patients one year of age and older, with newly diagnosed Philadelphia chromosome-positive, or Ph+, acute lymphoblastic leukemia in combination with chemotherapy.
Achillion Pharmaceuticals, Inc. (ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by disorders of the complement system, today announced that the Company’s Board of Directors has elected Nicole Vitullo Chair. Ms. Vitullo is a partner with Domain Associates LLC and has been a member of Achillion's Board of Directors since September 2010.
CORAL GABLES, FL / ACCESSWIRE / December 31, 2018 / With the new year only a few short moments away, the healthcare sector is electrified with excitement given that industry has shown tremendous growth over the last few months, as experts and professionals in the field have worked on developing technologies to improve the quality of care for patients on a global scale. Premier Health Group (PHGRF) (PHGI), Akers Biosciences Inc (AKER), vTv Therapeutics Inc (VTVT), and Achillion Pharmaceuticals, Inc (ACHN) represent 4 healthcare stocks to watch on Monday. Premier Health Group (PHGRF) (PHGI) is a company that is dead-set on investing in the development of innovative, high tech treatment solutions for patients in the primary care space.
Achillion's (ACHN) shares rise following the announcement of positive interim data from early to mid-stage studies evaluating its factor D inhibitors ??? ACH-4471, ACH-5228 and ACH-5548.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 17) Endocyte, Inc. (NASDAQ: ECYT ) Down In The Dumps (Biotech ...
NEW YORK, NY / ACCESSWIRE / December 18, 2018 / Shares of Achillion Pharmaceuticals were in the red on Monday as traders waited for interim clinical-trial data from the company. Synergy Pharmaceuticals saw its shares explode on news from Cipher Pharmaceuticals Inc. announcing that its New Drug Submission for plecanatide for irritable bowel syndrome with constipation ("IBS-C") has been accepted by Health Canada. Cipher acquired the Canadian rights to develop, market, distribute and sell plecanatide from Synergy earlier this year.
Achillion Pharmaceuticals, Inc. (ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement mediated disorders, today reported interim results for the Company’s Phase 2 trials of its first-generation oral factor D inhibitor, ACH-4471, as well as Phase 1 pharmacokinetics and potency data for its next-generation factor D inhibitors, ACH-5228 and ACH-5548. “These compelling findings underscore the momentum for Achillion and our factor D portfolio as we advance three oral small molecule compounds through clinical development.